The most important new treatments for osteoporosis fall into two groups: anabolic drugs that actively build new bone, such as romosozumab, teriparatide, and abaloparatide, and newer antiresorptive drugs such as denosumab that powerfully slow bone breakdown. Alongside bisphosphonates, these options let clinicians match treatment to a patient’s fracture risk, often starting with a bone builder in the highest-risk patients and following with a drug that locks in the gains.
Below I explain how osteoporosis develops, how it is diagnosed, and how each newer therapy fits alongside established care.
What Osteoporosis Is and Why It Develops
Osteoporosis is a skeletal disorder in which low bone mass and deteriorating bone architecture make bones fragile and prone to fracture. Bone is living tissue that is constantly remodeled: osteoclasts break down old bone and osteoblasts lay down new bone. When breakdown outpaces formation for years, bones become porous and weak.
The most common driver is the fall in estrogen after menopause, since estrogen normally restrains osteoclast activity. Men are also affected, particularly with age. Other risk factors include:
- Older age and a family history of hip fracture
- Low body weight
- Long-term glucocorticoid (steroid) use
- Hyperthyroidism, rheumatoid arthritis, and conditions that impair absorption
- Smoking, excess alcohol, and physical inactivity
- Low calcium and vitamin D intake
For a clinician-focused summary of the full treatment landscape, see our overview of osteoporosis treatment approaches.
The Biology Behind the New Drugs
Newer therapies were designed around two signaling systems that control remodeling.
The RANK/RANKL/OPG pathway
RANKL is a signal that switches on osteoclast formation and activity. Its natural brake is osteoprotegerin (OPG). When RANKL dominates, bone resorption rises. Blocking RANKL is how denosumab works.
The Wnt pathway and sclerostin
The Wnt signaling pathway drives osteoblasts to build bone. Sclerostin, a protein made by bone cells, dampens this pathway. Blocking sclerostin releases the brake on bone formation, which is the basis for romosozumab.
Diagnosis: Where Treatment Decisions Start
Osteoporosis is often silent until a fracture of the hip, spine, or wrist. Height loss, a stooped posture, or sudden back pain can signal vertebral fractures. The standard test is a DEXA scan (dual-energy X-ray absorptiometry), which reports bone density as a T-score compared with a healthy young adult.
| T-score | Category |
|---|---|
| -1.0 or higher | Normal bone density |
| Between -1.0 and -2.5 | Low bone mass (osteopenia) |
| -2.5 or lower | Osteoporosis |
| -2.5 or lower plus a fragility fracture | Severe (established) osteoporosis |
Clinicians often combine the T-score with the FRAX tool, which estimates 10-year fracture probability from clinical risk factors. A recent fracture, very low T-score, or multiple vertebral fractures marks a patient as very high risk, which is where the newer drugs are most often used.
Established Treatments
Bisphosphonates such as alendronate and risedronate (weekly or monthly tablets) and zoledronic acid (a yearly infusion) remain first-line for most patients. They bind to bone and inhibit osteoclasts. Rare but important side effects with long-term use include atypical femoral fractures and osteonecrosis of the jaw, which is why many patients take a planned “drug holiday” after several years.
Selective estrogen receptor modulators (SERMs) such as raloxifene, and menopausal hormone therapy in suitable women, are other established options. All treatment works best with adequate calcium and vitamin D; our article on the role of supplements in osteoporosis management covers this in detail.
Newer Treatments for Osteoporosis
| Drug | How it works | How it is given | Key points |
|---|---|---|---|
| Denosumab | Antibody that blocks RANKL | Injection every 6 months | Must not be stopped without follow-on therapy |
| Teriparatide | Parathyroid hormone analogue; builds bone | Daily self-injection, usually for a limited course | Followed by an antiresorptive |
| Abaloparatide | PTH-related peptide analogue; builds bone | Daily self-injection, limited course | Followed by an antiresorptive |
| Romosozumab | Antibody that blocks sclerostin; builds bone and reduces resorption | Monthly injections for 12 months | Not used after recent heart attack or stroke |
Denosumab
Denosumab reduces vertebral, nonvertebral, and hip fractures in postmenopausal women. Unlike bisphosphonates, its effect wears off quickly. Stopping it abruptly can trigger a rebound in bone loss and multiple vertebral fractures, so a transition plan, usually to a bisphosphonate, is essential.
Anabolic agents
Teriparatide, abaloparatide, and romosozumab actually rebuild bone rather than just slowing loss. In patients at very high risk, guidelines increasingly favor starting with an anabolic drug, then consolidating with an antiresorptive. This “sequence” matters: gains from bone builders fade unless they are followed by maintenance therapy.
Choosing between options
No single drug is right for everyone. When I discuss options with a patient, we weigh fracture history, T-score, kidney function, heart and stroke history, dental health, and how comfortable they are with injections. Cost and access also play a real role, since the anabolic drugs are more expensive and are often reserved for people who meet specific criteria.
Before starting any of these medicines, clinicians usually check blood calcium, vitamin D, and kidney function, and recommend a dental review if invasive dental work is planned. Low vitamin D should be corrected first, as it can blunt the response to treatment.
Lifestyle measures that support every drug
Medication works best as part of a broader plan. Weight-bearing and resistance exercise helps maintain bone and muscle strength, while balance training lowers the chance of falls. Stopping smoking, keeping alcohol moderate, and making the home safer with good lighting and fewer trip hazards all reduce fracture risk. These measures cost little and help every patient, whichever medicine they take.
Key Takeaways
- New treatments for osteoporosis include denosumab and three anabolic drugs: teriparatide, abaloparatide, and romosozumab.
- Anabolic drugs are usually reserved for very high-risk patients and are always followed by an antiresorptive.
- Denosumab should never be stopped without a follow-on plan.
- Calcium, vitamin D, exercise, and fall prevention support every drug option.
- Research continues into better sequencing and longer-lasting therapies; you can read more about current strategies and future directions in osteoporosis treatment.
For every bone-health topic in one place, see our osteoporosis guide.
Frequently Asked Questions
What is the newest treatment for osteoporosis?
Romosozumab is among the most recent additions. It blocks sclerostin, both increasing bone formation and reducing breakdown, and is given as monthly injections for one year before switching to maintenance therapy.
Are bone-building drugs better than bisphosphonates?
They are not better for everyone. For patients at very high fracture risk, anabolic drugs can produce faster gains in bone density, but for most people bisphosphonates remain an effective, convenient first choice.
Can I stop denosumab if I feel fine?
Not without talking to your doctor. Bone loss can rebound quickly after stopping, raising the risk of spine fractures, so a follow-on medicine is normally started.
Do I still need calcium and vitamin D on these new drugs?
Yes, in most cases. Adequate calcium and vitamin D help the medicines work and reduce the risk of low calcium, particularly with denosumab.
